| Literature DB >> 20004097 |
Serge Léger1, W Cameron Black, Denis Deschenes, Sarah Dolman, Jean-Pierre Falgueyret, Marc Gagnon, Sébastien Guiral, Zheng Huang, Jocelyne Guay, Yves Leblanc, Chun-Sing Li, Frédéric Massé, Renata Oballa, Lei Zhang.
Abstract
A series of stearoyl-CoA desaturase 1 (SCD1) inhibitors were developed. Investigations of enzyme potency and metabolism led to the identification of the thiadiazole-pyridazine derivative MF-438 as a potent SCD1 inhibitor. MF-438 exhibits good pharmacokinetics and metabolic stability, thereby serving as a valuable tool for further understanding the role of SCD inhibition in biological and pharmacological models of diseases related to metabolic disorders. Copyright 2009 Elsevier Ltd. All rights reserved.Entities:
Mesh:
Substances:
Year: 2009 PMID: 20004097 DOI: 10.1016/j.bmcl.2009.11.111
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823